Ancillary therapy of respiratory disease in food animals: What can we give in addition to an antibiotic? (Proceedings)
Aug 01, 2010
CVC IN KANSAS CITY PROCEEDINGS
In this session we will take an evidence-based medicine approach to ancillary therapy of bovine respiratory disease. The literature reviewed here is not presented as being all-inclusive, but rather as a summary of many commonly cited articles on these subjects. The citations are primarily peer reviewed, but some are from freedom of information (FOI) summaries and a few are proceedings papers or abstracts.
No published data could be found to support the use of Vitamin B or C, vaccines (at the time of therapy), antihistamines, anthelmintics, probiotics, or oral electrolytes in the ancillary therapy of bovine respiratory disease. For the purposes of this presentation, we will examine the published data concerning the use of steroidal and non-steroidal anti-inflammatory drugs as ancillary therapy for respiratory disease.
These findings aren't that surprising since dexamethasone, at 0.04 mg/kg daily (0.9 ml/100 lbs of a 2 mg/ml solution) for 3 days, is used as a research model to suppress neutrophil function in cattle. This model was utilized in small Holstein calves in conjunction with induced Haemophilus somnus pneumonia to demonstrate that this dexamethasone regimen increased lung lesions. An IBR latency model in rabbits demonstrated that a single high-dose injection of dexamethasone (2.8 mg/kg) could bring about reactivation of latent BHV-1. Other studies have failed to show significant differences in treatment response using prednisone acetate, methyl prednisolone, or methyl-prednisolone-succinate in natural and induced respiratory disease.,
Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
The NSAID currently labeled specifically for BRD in the United States is Flunixin meglumine (Banamine? Injectable Solution, Schering-Plough Animal Health). The label includes indications for the control of pyrexia associated with bovine respiratory disease, acute bovine mastitis, and endotoxemia. The inflammation indication on the label is for the control of inflammation in endotoxemia. Flunixin meglumine is considered an effective analgesic, anti-inflammatory, and antipyretic. The mechanism of action is cyclooxygenase inhibition.
The outlines below summarize published studies and the Freedom of Information (FOI) summaries of flunixin meglumine effects on respiratory disease outcome.
Flunixin BRD study 1: 12 week old dairy calves, induced Pasteurella haemolytica pneumonia 4 treatment groups - no treatment, oxytetracycline (10 mg/kg IM SID for 3 days), flunixin meglumine (2.2 mg/kg IV SID for 3 days), and both oxytetracycline and flunixin meglumine.